Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12019905 | 0.84 | ALDH1A1 (0.33) | ALDH1A1EPHX1KMT2ANR1H4 | |
| SCHEMBL6566358 | 0.83 | GABRP (0.45) | ALDH1A1KMT2ANR1H4 | |
| SCHEMBL1226217 | 0.82 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2EPHX1KMT2ANR1H4 | |
| SCHEMBL13817698 | 0.80 | EPHX1 (0.35) | GAARAB9ASMN1; SMN2EPHX1HPGD | |
| SCHEMBL27160173 | 0.79 | EPHX1 (0.39) | ALDH1A1SMN1; SMN2EPHX1HPGDKMT2A | |
| SCHEMBL13817814 | 0.79 | SMN1; SMN2 (0.37) | ALDH1A1GAARAB9ASMN1; SMN2EPHX1 | |
| SCHEMBL23891761 | 0.78 | NR1H4 (0.36) | NR1H4 | |
| SCHEMBL28241871 | 0.77 | EPHX2 (0.49) | EPHX1HPGDKMT2ACA12CA1 | |
| SCHEMBL17715691 | 0.77 | ALDH1A1 (0.42) | ALDH1A1EPHX1HPGDKMT2ACA12 | |
| SCHEMBL4742218 | 0.77 | ALDH1A1 (0.42) | ALDH1A1EPHX1HPGDKMT2ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086925-B1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INT (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-1067118-B1 | Cyclopentylalkyl-nitriles and the use of odoriferous cyclopentylalkyl derivatives as fragrances | GIVAUDAN SA (CH) | 2004-03-31 | — | — | EP | disclosed |
| US-6441052-B1 | ALKANOL, ALDEHYDE, AND KETONE CYCLOPENTA DERIVATIVES; FRAGRANCES | GIVAUDAN SA (CH) | 2002-08-27 | — | — | US | disclosed |
| US-20020086901-A1 | CYCLOPENTYLALKYL-NITRILES | GIVAUDAN SA, A SWITZERLAND CORPORATION | 2002-07-04 | — | — | US | disclosed |
| US-6410000-B1 | PERFUME | GIVAUDAN SA (CH) | 2002-06-25 | — | — | US | disclosed |
| US-6399811-B1 | ORGANOLEPTIC | GIVAUDAN SA (CH) | 2002-06-04 | — | — | US | disclosed |
| EP-1067118-A1 | Cyclopentylalkyl-nitriles and the use of odoriferous cyclopentylalkyl derivatives as fragrances | Givaudan SA (CH) | 2001-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086901-A1 | CYCLOPENTYLALKYL-NITRILES | CCRL2, CBR1, CNR1 | ALDH1A1 479/4885GAA 4773/4885RAB9A 3407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.